Vitamin, Mineral and Amino Acid Supplement
98/100
This product looks safe
- Niacin: 74mg is 2.1× the Tolerable Upper Intake Level (35mg)
- 61% of ingredients have research evidence
C
Label Compliance Grade
What the Evidence Says
AI-generated · Qwen 3.6 · methodologyThis supplement provides protein and essential vitamins C and E, which support muscle maintenance and antioxidant functions. There is strong research evidence supporting the roles of these nutrients in general health. The product maintains a high safety score, indicating a low risk of adverse effects.
AI-generated summary based on research evidence. Not medical advice.
Alerts
Safety Alerts
Niacin: 74mg is 2.1× the Tolerable Upper Intake Level (35mg)
Label
Product Label
Details
Label Data
1 Packet(s)
Serving Size
30
Servings
Other Combinations
Product Type
61%
Evidence Coverage
Ingredients
Supplement Facts — Evidence Check
Calories
50 {Calories}
Total Carbohydrates
12 Gram(s)
(4% DV)
Protein
1 Gram(s)
(2% DV)
Vitamin C
324 mg
(540% DV)
15 IU
(50% DV)
Within RDA (0.7× RDA)
179 studies (A:3, B:90)
1.5 mg
(100% DV)
1.2× RDA — within safe limits
76 studies (A:0, B:33)
3 mg
(176% DV)
2.3× RDA — within safe limits
13 studies (A:0, B:1)
74 mg
(370% DV)
Exceeds UL by 2.1× (UL: 35 mg)
196 studies (A:5, B:63)
16 mg
(800% DV)
12.3× RDA — above typical dose (UL: 100 mg)
114 studies (A:3, B:35)
100 mcg
(25% DV)
Within RDA (0.2× RDA)
226 studies (A:10, B:105)
20.2 mcg
(337% DV)
8.4× RDA — above typical dose
139 studies (A:1, B:44)
18 mg
(184% DV)
3.6× RDA — above typical dose
2 studies — no high-quality reviews
3 mg
(21% DV)
Within RDA (0.3× RDA)
263 studies (A:6, B:134)
0.4 mg
(21% DV)
Within RDA (0.4× RDA)
37 studies (A:0, B:11)
25 mcg
(21% DV)
Within RDA (0.7× RDA)
199 studies (A:1, B:55)
L-Phenylalanine
505 mg
202 mg
Market median: 500.0mg (180 products)
5 studies (A:0, B:1)
Glycine
151 mg
Claims
Label Claims — Verification
Unverified
No Claim
Info
Product Information
Additional Information
Natural & Artificial Orange Flavored
30 packs of 0.44 oz
Metadata
Product Details
Research
Research Evidence
50
Research Sources
47
Avg Quality
28
Rct
13
Clinical Trial
5
Guideline
4
Systematic Review
A
Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.
B
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.
B
Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates
B
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].
B
[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].
B
Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.
B
Baseline-dependent effect of dopamine's precursor L-tyrosine on working memory gating but not updating
B
Effect of Amino Acid Supplementation on Iron Regulation after Endurance Exercise
C
Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression
Compare
Similar Products
View all Tyrosine products →This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.